ViaCell, Inc. (Nasdaq: VIAC) today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up. CB001 is an investigational therapy being studied as a potential therapeutic option for people who need stem cell transplants, such as bone marrow, for hematopoietic recovery after...

25/07/2006

http://www.lifelinecordblood.com/upload/20100622/1277211469-04635.pdf